Key result
A HAS-BLED score of ≥3 points identified patients with acute venous thromboembolism at an 8.7-fold increased risk of major bleeding complications during the first 6 months of VKA treatment.
Why the study?
Does a HAS-BLED score ≥ 3 identify patients at high risk of major bleeding during vitamin K-antagonist treatment for acute venous thromboembolism?
Cohort (n=537)
Yes
Does a HAS-BLED score ≥ 3 identify patients at high risk of major bleeding during vitamin K-antagonist treatment for acute venous thromboembolism?
The HAS-BLED score, originally designed for atrial fibrillation, effectively identifies acute VTE patients at high risk for major bleeding during the first 6 months of vitamin K-antagonist therapy.
Answers are grounded in this paper and cite their sources.
HAS-BLED ≥3 identifies higher major bleed risk in acute VTE on VKA; supports extension to this population but leaves validation open.
OBJECTIVE: The HAS-BLED score enables a risk estimate of major bleeds in patients with atrial fibrillation on vitamin K-antagonists (VKA) treatment, but has not been validated for patients with venous thromboembolism (VTE). We analyzed whether the HAS-BLED score accurately identifies patients at high risk of major bleeds during VKA treatment for acute VTE. METHODS: Medical records of 537 patients with acute VTE (primary diagnosis pulmonary embolism in 223, deep vein thrombosis in 314) starting VKA treatment between 2006-2007 were searched for items on the HAS-BLED score and the occurrence of major bleeds during the first 180 days of follow-up. The hazard ratio (HR) for the occurrence of major bleeds comparing non-high with high-risk patients as defined by a HAS-BLED score ≥ 3 points was calculated using Cox-regression analysis. RESULTS: Major bleeds occurred in 11/537 patients (2.0%, 5.2/100 person years, 95% CI 2.8-9.2). Cumulative incidences of major bleeds were 1.3% (95% CI 0.1-2.5) in the non-high (HAS-BLED < 3) and 9.6% (95%CI 2.2-17.0) in the high-risk group (HAS-BLED ≥ 3), (p <0.0001 by Log-Rank test), with a HR of 8.7 (95% CI 2.7-28.4). Of the items in the HAS-BLED score, abnormal renal function (HR 10.8, 95% CI 1.9-61.7) and a history of bleeding events (HR 10.4, 95% CI 2.5-42.5) were independent predictors of major bleeds during follow-up. CONCLUSION: Acute VTE patients with a HAS-BLED score ≥ 3 points are at increased risk of major bleeding. These results warrant for correction of the potentially reversible risk factors for major bleeding and careful International Normalized Ratio monitoring in acute VTE patients with a high HAS-BLED score.
No takes yet. Share an insight, caveat, or question.
Kooiman et al. (2015) conducted a cohort in Acute venous thromboembolism (VTE) (n=537). HAS-BLED score ≥ 3 (high risk) vs. HAS-BLED score < 3 (non-high risk) was evaluated on Occurrence of major bleeding events (HR 8.7, 95% CI 2.7-28.4, p=<0.0001). A HAS-BLED score of ≥3 points identified patients with acute venous thromboembolism at an 8.7-fold increased risk of major bleeding complications during the first 6 months of VKA treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: